LINKCARE HEALTH SERVICES SL

Their core work

Linkcare Health Services is a Barcelona-based digital health SME specialising in care coordination and chronic disease management technology. Their participation in PRECeDI — a Marie Curie project on personalised prevention of chronic diseases — indicates they bring a clinical technology or health information systems perspective to academic research consortia, translating scientific insights into practical care delivery tools. Their involvement in MOGLYNET, focused on atherosclerosis and metabolic disease, suggests expertise at the intersection of cardiovascular health and genomics-informed treatment approaches. As a private company in these MSCA networks, they most likely serve the role of industry end-user or implementation partner, grounding research in real-world health service delivery.

What they specialise in

How they've shifted over time

Both H2020 projects began in 2015, which means the organisation's EU research engagement is effectively a single time window — no later-period keywords exist to compare against. At that moment, their focus was clearly on personalised medicine, genomics, chronic disease, and health systems. There is no evidence of a shift or expansion within the H2020 dataset, either because their EU project activity ended after 2015 or because later work is not captured here.

Their EU research footprint is narrow and dated to 2015; without more recent project involvement, it is unclear whether they have deepened their health-tech specialisation or shifted focus entirely.

How they like to work

Linkcare has never coordinated a Horizon 2020 project, joining exclusively as a participant or third-party partner. Both their projects are MSCA schemes — research staff exchange and joint doctoral programmes — where private companies typically provide industry mentoring, real-world testing environments, or access to clinical data rather than leading the scientific agenda. Their 23 unique partners across 11 countries come from these two large MSCA consortia, reflecting the scheme's design rather than an independently built network.

Linkcare has touched 23 consortium partners across 11 countries, an unusually broad reach for an organisation with only two projects — a direct result of participating in MSCA schemes that are structurally large and multi-country. Their actual recurring relationships within these consortia are not distinguishable from the available data.

What sets them apart

Linkcare occupies a niche as a Spanish digital health SME that bridges clinical care delivery and EU-funded genomics and personalised medicine research. For consortium builders, their value lies in offering an industry and end-user perspective on chronic disease management — a role that many MSCA and clinical research projects require but few private health companies actively fill. However, their limited and dated EU project record means any collaboration would require direct validation of their current capabilities and product offering.

Highlights from their portfolio

• PRECeDI
  Their only directly funded H2020 project — a Marie Curie RISE network on personalised prevention of chronic diseases using genomics — represents their clearest evidence of engagement with precision health research.
• MOGLYNET
  Participation as a third-party (unfunded) partner in a glycolysis-modulation project for atherosclerosis treatment demonstrates a secondary connection to metabolic and cardiovascular disease research beyond their core chronic disease focus.